USPTO issues Inter Partes Reexamination Certificate of key LNA patent

    USPTO issues Inter Partes Reexamination Certificate of key LNA patent

  PR Newswire

  HOERSHOLM, Denmark and SAN DIEGO, April 5, 2013

HOERSHOLM, DenmarkandSAN DIEGO, April 5, 2013 /PRNewswire/ --Santaris
Pharma A/S, a clinical-stage biopharmaceutical company focused on the
discovery and development of RNA-targeted therapies, today announced that the
USPTO issued an Inter Partes Reexamination Certificate for U.S. Pat. No.
6,770,748 (the '748 patent) on April 1, 2013. The certificate, which follows
a decision by the USPTO to dismiss an appeal that had been filed by Isis
Pharmaceuticals during the proceeding, confirms the patentability of original
claims 1-4, amended claim 5, and five new claims (claims 6-10) added by
Santaris during the proceeding.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )

The '748 patent is a continuation-in-part of U.S. Pat. No. 6,268,490 (the
'Imanishi Patent). The 'Imanishi patent was previously subject to an ex parte
reexamination request also brought by Isis, which ended with the USPTO issuing
an Ex Parte Reexamination Certificate on December 6, 2011, confirming the
patentability of all the original claims. The Imanishi and '748 patents claim
rights to the Locked Nucleic Acid (LNA) or Bicyclic Nucleic Acid (BNA)
chemical structure used for developing antisense molecules.

Commenting on the USPTO decision,Henrik Stage, President & CEO of Santaris
Pharma, said: "We are delighted that these lengthy procedures have been
successfully concluded with USPTO confirming the patentability of our '748 and
'Imanishi patents. These are two of our fundamental patents, which provide
broad protection for our state-of-the-art antisense drug platform based on the
Locked Nucleic acid/Bicyclic Nucleic Acid chemistries."

Santaris is represented by Eric Steffe and John Covert of Sterne, Kessler,
Goldstein & Fox, located in Washington, D.C.

About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combines the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver LNA-based drug candidates against
RNA targets, both mRNA and microRNA, for a range of diseases including
infectious and inflammatory diseases, cardiometabolic disorders, cancer and
rare genetic disorders. LNA-based drugs are a promising new class of
therapeutics that are enabling scientists to develop drug candidates that
target previously inaccessible clinical pathways. The LNA Drug Platform
overcomes the limitations of earlier antisense and siRNA technologies to
deliver potent single-stranded LNA-based drug candidates across a multitude of
disease states. The unique combination of small size and very high affinity
allows this new class of drug candidates to potently and specifically inhibit
RNA targets in many different tissues without the need for complex delivery
vehicles. The most important features of LNA-based drugs include excellent
specificity providing optimal targeting; increased affinity to targets
providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S Santaris Pharma A/S is a privately held
clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies. The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combine the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver potent single-stranded LNA-based
drug candidates across a multitude of disease states. The company's research
and development activities focus on infectious diseases and cardiometabolic
disorders, while partnerships with major pharmaceutical companies include a
range of therapeutic areas including cancer, cardiovascular disease,
infectious and inflammatory diseases, and rare genetic disorders. The company
has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer,
GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent
estate, the company holds exclusive worldwide rights to manufacture, have
manufactured and sell products that contain LNA as an active ingredient for
studies performed with a view to obtaining marketing approval. Santaris Pharma
A/S, founded in 2003, is headquartered in Denmark with operations in the
United States. Please visit www.santaris.com for more information.

Website: http://www.santaris.com
Contact: Henrik Stager, President & CEO, Cell: +45-40-26-09-00, E-mail:
hs@santaris.com, www.santaris.com; Henrik Oerum, CSO, Cell: +45-2834-6474,
e-mail: hoe@santaris.com, www.santaris.com
 
Press spacebar to pause and continue. Press esc to stop.